Antonio J. Vallejo‐Vaz

Author

Also Known As

A J Vallejo-Vaz, A Vallejo-Vaz, A. J. Vallejo-Vaz, A. Vallejo-Vaz, A.J. Vallejo-Vaz, A.J. Vallejo-Váz, Antonio J. Vallejo-Vaz, Antonio J Vallejo Vaz, Antonio J Vallejo-Vaz, Antonio J. Vallejo

124

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Imperial College London Hospital Universitario Virgen del Rocío Universidad de Sevilla Instituto de Biomedicina de Sevilla Amsterdam UMC Location University of Amsterdam

About

Antonio J. Vallejo‐Vaz is an author at Imperial College London specializing in public health, medicine, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	811
2	Public Health	8	9	993
3	Health Sciences	1	1	55
4	Diabetes	1	1	55
5	Endocrinology	1	1	55

Antonio J. Vallejo‐Vaz

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons, The Lancet Family MedicineMetabolic SyndromeLipid DisorderCardiovascular DiseaseHealth Policy	2021	285
Olive Oil Polyphenols Decrease Blood Pressure and Improve Endothelial Function in Young Women with Mild Hypertension Rafael Moreno‐Luna, Rocío Múñoz‐Hernández, María Luisa Miranda, American Journal of Hypertension	2012	239
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Antonio J. Vallejo‐Vaz, Martina De Marco, Christophe Stevens, Atherosclerosis Family MedicineLipid DisorderPrimary CareCardiovascular EpidemiologyHealth Policy	2018	228
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial Antonio J. Vallejo‐Vaz, Rana Fayyad, S. Matthijs Boekholdt, Circulation	2018	189
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study Tycho R. Tromp, Merel L. Hartgers, G. Kees Hovingh, The Lancet Metabolic SyndromeLipid DisorderCardiovascular DiseaseGenetic EpidemiologyWorldwide Experience	2022	189
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above Antonio J. Vallejo‐Vaz, Michele Robertson, Alberico L. Catapano, Circulation	2017	180
Familial hypercholesterolaemia: A global call to arms Antonio J. Vallejo‐Vaz, Sreenivasa Rao Kondapally Seshasai, Della Cole, Atherosclerosis Metabolic SyndromeFamily MedicineLipid DisorderCardiovascular DiseaseHyperlipidemia	2015	178
Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration Antonio J. Vallejo‐Vaz, Asif Akram, Sreenivasa Rao Kondapally Seshasai, Atherosclerosis Supplements	2016	112
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study Kanika Dharmayat, Antonio J. Vallejo‐Vaz, Christophe Stevens, The Lancet	2023	71
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials Kausik K. Ray, Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Atherosclerosis	2019	66

Page 1